I ka kaohi o ka maʻi type 1, hāʻawi ʻia ka hana nui i ka ʻomo ʻana i ka insulin. Me ka ʻano o nā maʻi maʻi 2, e noho pū nā hana kōkua me nā mea lapaʻau. ʻOkoʻa kekahi ʻo Diet. I ka hihia mua, ʻo ia ke ʻano o ka mālama ʻana. Ma ka lua - meaʻai i kahi wahi alakaʻi. ʻO nā lāʻau hōʻemi i ke kō koko koko ua kapa ʻia nā papa. Hoʻomaopopo kēia i ko lākou koho i nā inikini insulin injections. Ua kau ʻia nā lāʻau lapaʻau e nā endocrinologist. Pono ʻoe e ʻike i ka inoa olakino ākea o ka hui a me ke ʻano lāʻau lapaʻau kūikawā o ka loea hypoglycemic.
ʻO ka hōʻailona o ka lāʻau hypoglycemic waha
ʻO ka papa inoa o nā mea lapaʻau pharmacological no nā maʻi endocrinological a nui. ʻAʻohe inoa inoa kūʻai hoʻokahi no kēlā me kēia lāʻau lapaʻau. Hoʻokomo ʻia nā lāʻau lapaʻau no ka hoʻohaʻahaʻa i ke kōhi koko koko e like me nā insulins. Aia nā papa ma nā palaki a i ʻole nā kaula pepa. Hoʻopili ʻia lākou ma nā pahu pepa ma laila e hōʻike ʻia ai ko lākou mau inoa a me nā ʻike hou aʻe (ke ola moe, nā kūlana mālama). Pono e hoʻomanaʻo ʻia ua pāpā ʻia nā huahana i pau.
He mea nui e ʻike e pili ana i ka lāʻau lapaʻau hypoglycemic:
- ka hoʻomaka ʻana o ka hana (ua manaʻo ʻia ʻo ia mai ka manawa e hoʻokipa ai);
- ka manawa ke hoʻomaka nei ka hopena e hōʻike me ke kaha kūpono;
- ka lōʻihi o ka manawa kiʻekiʻe;
- ka hopena hope loa o ka wehe ʻana i ka lāʻau.
Hiki i ka mea hana like ma ke ʻano o nā papa nui a me nā liʻiliʻi. No ka laʻana, kahi ʻano mannyl ʻē aʻe i loaʻa, kēlā me ia, 0,005 g a me 0.0015 g.ʻO kahi mea maʻi me ka maʻi diabetes e nānā pono a ʻaʻole wale i ka inoa o ka lāʻau lapaʻau, akā naʻe i nā mea i ʻōlelo ʻia e ia e ke kauka.
No nā poʻe ʻē aʻe a me hoʻokahi no ka hoʻokahi kanaka, akā i kahi ʻano ʻokoʻa, e hana nā papa i ko lākou ala ponoʻī. Hoʻonui nui ka hōʻailona ʻano pilikino i nā lāʻau lapaʻau. No ka laʻana, ʻo ka lōʻihi o ka hana o ka chlorpropamide e pili ana me PSM i paʻa i nā hola 60, o ka buformin mai ka pūʻulu biguanide - 6 mau hola.
Pono ka mea maʻi endocrinological i kahi koho kūpono no ka hoʻōla kūpono a i ʻole ka ʻema āpau āpau. ʻO ka ʻokoʻa nui ka ikaika o nā hopena o nā lāʻau lapaʻau. No laila, ʻikeʻia ka butamide e nāwaliwali, maʻi iki ka maʻi maʻamau, a ʻo ka maninil ke alakaʻi.
Nā kikoʻina kikoʻī o nā ʻoihana hypoglycemic, hui PSM
Oral (ua ʻai ʻia ma o ka oral waha) nā papa no ka hoʻohaʻahaʻa i ke kō o ke koko me nā mea ʻalekina a me nā ʻano kemana.
Hoʻokomo ʻia ma kēia, ʻokoʻa nā huakaʻi ʻehā:
Pehea e mālama ai i ka maʻi maʻi- ʻO nā lāʻau lapaʻau e hoʻoikaika ai i ka synthesis (hoʻokumu) ʻana i ka pono o ka insulin i ka mākaukau sulfonylurea (PSM).
- Hoʻonui ka Biguanides i ka mālamalama o nā pūpuna i ka hormone.
- Hoʻololi ka lohi o ka glucosidase alpha i ka lawe ʻana o ka glucose i loko o ke koko i loko o ka ʻōpū.
- Hoʻonui ka Sensitizers (glitazones) i ka hoʻoliʻi ʻana o ka insulin i nā ʻāpana o ke kino.
Ma ka hoʻohālikelike ʻia, ua hoʻohana ʻia ʻo PSM mai nā pūʻulu ʻekolu o nā hanauna no ka mālama ʻana i ke ʻano maʻi diabetes like 2. ʻO nā lāʻau lapaʻau mua, akā ua loaʻa kahi kaulana akāamide. I kēia manawa kokoke loa ia. Hōʻike ka lua o ka hanauna e ka maʻi a me nā mannil. Hana lākou me ka ʻoi aku ka maikaʻi. Hoʻokumu ʻo PSM i ka pancreas e hana i ka hormone, e ʻae ana iā ʻoe e hoʻohaʻahaʻa i ke kō koko.
ʻO Amaril - kahi mākaʻikaʻi o nā subekema pharmacological ma hope o PSM, i loaʻa ka nui o nā pono i mua o kāna mau mua. ʻIke ʻia nā lāʻau lapaʻau o kēia ʻano maʻi i nā mea maʻi ma lalo o nā inoa inoa: glimepiride, repaglinide (novonorm), nateglinide (starlix).
ʻO ka hana lōʻihi ma ka hoʻohana ʻana iā biguanides i kekahi mau ʻāina, ʻoiai ʻo ʻAmelika Hui Pū ʻIa, ua hoʻopau pono i kā lākou hoʻohana ʻana
ʻO Biguanide Group
Me ka mālama kūpono, kōkua nā lāʻau lapaʻau i nā maʻi maʻi 2 ʻano nui e hōʻemi ana i ko lākou glycemia. Ma mua o ke kau ʻana i nā lāʻau lapaʻau e hoʻohaʻahaʻa i ke kōkē o ke koko, ka mea nui o ka biguanides, pono ka manaʻo o ka endocrinologist i nā contraindications o ka mea maʻi mai nā papa hana o ka kūnao a me ka cardiac.
ʻO ka mea kūikawā o nā biguanides ko lākou:
- mai hoʻōla i ka pancreas e hana i ka mea pono i kona ʻimi ponoʻī e like, me ka ʻimi i nā kaha hope o ke kino;
- hoʻemi i ka komo ʻana o nā momona a me nā hukū mai i loko o ke koko i loko o ke koko;
- ʻoi aku ka maikaʻi o ka glucose, ʻoi aku ka maikaʻi o nā mea kanu piha;
- ʻaʻole ke alakaʻi i ka hoʻouka ʻana i ka glycemia (kahi hemo koi i nā pae gula).
Hoʻomaopopo ʻia kahi maʻi maʻi hilahila i nā hilahila haʻahaʻa: make nui nā kihi o nā lolo, aia ka maikaʻi o ka coma. Pono kēlā me kēlā me kēia maʻi e hoʻomaopopo e hoʻomaopopo i kā lākou mau hōʻailona liʻiliʻi o kahi kūlana wikiwiki. Hiki ke hoʻopau hou ʻia ia ma ka hoʻohana ʻana i nā hāmeʻa kūlohelohe maʻalahi, ʻoi aku ka maikaʻi i nā ʻano wai (lemonade, kī ʻona, wai wai).
ʻO nā hōʻailona mua o ka hypoglycemia
Ke koena i nā hui o ke kō
Hoʻokō ʻia ka hana o nā inhibitors alpha-glycosidase (acarbose-glucobay, miglitinol). ʻAʻole lākou e pili pono i nā kiko peripheral a me nā cell beta o ka pancreas. Hōʻalo nā mea hoʻonani i ka hoʻokaʻawale ʻana i nā glucose i ka hapa hope loa o ka ʻono o ka gastrointestinal. ʻO ka kalapona o ka nui i loko o ka meaʻai ua wāwahi ʻia i ka ʻōpū ma luna o nā pūpū māmā. Ma hope o kēlā, ke hoʻoili ʻia nei ka glucose i ke koko ma kona ʻāpana.
ʻO ka hana o nā enzymes cleavage e kāohi i nā mea paʻa alpha-glycosidase. Hoʻokahi i ka ʻāpana haʻahaʻa, ʻaʻole i hoʻopaʻa ʻia nā kōlepa paʻakikī i loko o ke koko. ʻO ia ke kumu a ka huehue, ke kolo ʻana, a me nā mea hoʻolapalapa ke hanana a me nā hopena pili i ka wā e lawe ai i nā paila e hoʻohaʻahaʻa i ke kō koko.
Hoʻopā maikaʻi nā pale a me nā hypoglycemic ʻē aʻe, e komo pū i ka insulin. Akā ʻaʻole hiki iā ʻoe ke hāʻawi iā lākou iā ʻoe iho. Hiki ke hoʻohana ʻia e nā pākeke. Lawe i nā manawa 3 i ka lā ma mua o ka papaʻaina, me ka mālama ʻana i ka ʻaole. No laila, ʻo ka nui loa o ka nui o ka lā o ka glucoseoboy he 0.6 g.
ʻO ka mea kūkākūkā mua o nā sensitizers (glitazones) - resulin - he ʻike ʻole kūleʻa o ka noi ma ka hoʻomaʻamaʻa honua. Ma Lusia, ʻaʻole i kākau inoa ʻia ʻo ia. Ua manaʻo ʻia he lāʻau lapaʻau no ka hoʻohaʻahaʻa i ke kō koko koko e hoʻololi i ke ola o nā mea maʻi me ka maʻi diabetes-hilinaʻi me ka maʻi maʻamau, ka mea i ʻae ʻole i ka synthesized hormone e hele mai mai waho. Me kāna kōkua, hiki i ka hōʻemi ʻana i ka nui o nā inikini a me nā dosis insulin. ʻO ka hopena ʻaoʻao o ka resulin ka luku ʻana i ka naʻau. Pono nā mea maʻi e hana i ka hoʻāʻo koko biochemical i kēlā me kēia mahina.
ʻO ka mea i hōʻike i ka hopena o nā pōpipīpī hou - nā actos - nā endocrinologists e kuhikuhi pū ʻia i hoʻokahi ʻāpana hoʻokahi a hui pū ʻia me PSM, biguanides no ka maʻi diabetes type 2. Ke hoʻomau nei nā noi ʻana o ka hoʻohana pono ʻana o ka lāʻau hou.
Hiki i ka mālama ʻana i nā actosomes i kūlike me ka insulin
Nā Hōʻailona:
- hoʻonui i ka ʻike o ka momona a me ka kiko o ka ʻiʻo i ka hormone;
- hoʻemi i ka hoʻokumuʻana o ka glucose i loko o ka ate;
- ho'ēmi i ka hōʻemi o ka hoʻopiʻi cardiovascular.
ʻO ka nele o nā actos e hoʻomaopopo ʻia ka hoʻonui ʻana i ka paona kino o ke kanaka. He nui nā ʻāina e hana ana i nā paila haʻahaʻa -. Ua manaʻo ʻia ʻo nā ʻoihana kaulana o ka hui pū ʻana o ka German-French Aventis, Danish Novo Nordics, American Novartis, Lilly.
Hoʻohana ʻia me nā lāʻau lapaʻau hypoglycemic a me nā contraindications
Ma muli o ka hoʻolālā lapaʻau i koho ʻia no ka maʻi diabetes, he nui nā hiʻohiʻona o ka papa o ka maʻi type 2. ʻO ka lawe ʻana i ka lāʻau lapaʻau ma mua wale nō ka maʻalahi o ka hāʻawi ʻana i kahi maʻi. A ʻo ka pōʻai a me pehea?
E noʻonoʻo pono nā mea i ka wā e lawe ai i kahi papa pā:
- ka 'uʻana o ka ʻeha a me nā ʻili;
- no ka manawa a me nā mea kahi e kuhi ʻia ai ke kino mai ke kino;
- pehea ia e kūpono ai i nā poʻe i ke elemakule;
- aia kekahi hopena hoʻohui;
- nā hopena maikaʻi loa.
ʻO ka maʻamau, kahi kauka, ma ka ʻike ʻana i ka maʻi maʻamau ʻo 2, ke kuhikuhi ana i kaʻai liʻiliʻi haʻahaʻa me ka liʻiliʻi o ka momona a me ka hoʻoikaika kino olakino i ka mea maʻi. Ua kuhikuhi i ka lāʻau lapaʻau, no nā mea hoʻomaka - ka maʻi maʻi (ma ka liʻiliʻi a i ʻole a hōʻemi ʻia paha, hilinaʻi ʻia i nā hoʻāʻo glucose koko).
Pono nā papa hypoglycemic, ma ke ʻano he kānāwai, ʻelua e mālama ʻelua a ʻekolu paha i ka lā. Ma hope o ka lawe ʻana i loko o hoʻokahi hola, e ʻai ke kanaka maʻi. Hoʻokumu i nā hopena o nā hōʻike koko a me ke olakino maikaʻi, hiki ke hoʻololi pū ʻia nā lāʻau lapaʻau, hiki ke hoʻoponopono ʻia kā lākou hewa.
ʻO ka hana nui o ka hoʻohana ʻana i nā lāʻau lapaʻau e hoʻohaʻahaʻa i ke kō
Inā ʻaʻole ikaika ka lāʻau lapaʻau ikaika loa i ka nui loa (0,02 g i kēlā me kēia lā 4 papa) ʻaʻole ia e ʻae i ka hoʻōki ʻana i ka maʻi diabetes, ua make ka mea maʻi (ʻo ka hana maʻamau ke hana a hoʻomaha hoʻi, e nāwaliwali ana kona mau maka, ulu nā wāwae,) a laila e mau ʻia ka ʻike ʻia . ^ E Ha yM.
E pono paha no kēia e hele i ka haukapila. Ma kahi kahua hoʻomaha o kahi haukapila, ʻoi aku ka maʻalahi o nā poʻe loea e hoʻoholo inā hoʻololi i ka therapy insulin a i hoʻolōʻihi iā ia ma o ka hōʻeha ʻana o ka PSM a me biguanides. Aia kahi koho lapaʻau koho: nā pāpaʻi a me ke kō. Kuhi pinepine ʻia kahi kēkē i ka pō (10-20 mau kekona o ka hoʻomaka ʻana o ka hormone), i ke kakahiaka mālama lākou i nā paila.
Hiki i ke hypersensitivity i ka mea i loko o ka lāʻau lapaʻau ke kumu i nā hopena alia. Akā ʻo nā contraindications maʻamau i ka hoʻohana ʻana i nā papa i ke ʻano maʻi maʻi 1 a i ʻole ka hele ʻana o ka decompensation ma muli o ka maʻi ʻana, nā hōʻeha, nā hana hōʻoki, ka hapai. Ma ka ulia pōpilikia, koi ʻia ka mea maʻi i nā mea āpau e hōʻike i nā limahana lapaʻau e pili ana i ka pathology endocrine i kēia manawa.
